Oramed Pharmaceuticals Inc. (ORMP.TA)

ILA 879.9

(4.22%)

Market Cap (In ILA)

354.7 Million

Revenue (In ILA)

9.51 Million

Net Income (In ILA)

-128.65 Million

Avg. Volume

8617.00

Currency
ILA
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.501-900.0
PE
-
EPS
-
Beta Value
1.77
ISIN
US68403P2039
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Mr. Nadav Kidron Esq.
Employee Count
-
Website
https://www.oramed.com
Ipo Date
2017-07-13
Details
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.